KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares OutstandingShares Repurchased
Ratios

Royalty Pharma (RPRX) Long-Term Debt Issuances (2020 - 2025)

Historic Long-Term Debt Issuances for Royalty Pharma (RPRX) over the last 4 years, with Q3 2025 value amounting to $2.0 billion.

  • Royalty Pharma's Long-Term Debt Issuances changed N/A to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year increase of 55842.14%. This contributed to the annual value of $1.5 billion for FY2024, which is 32035.29% up from last year.
  • Royalty Pharma's Long-Term Debt Issuances amounted to $2.0 billion in Q3 2025.
  • In the past 5 years, Royalty Pharma's Long-Term Debt Issuances registered a high of $2.0 billion during Q3 2025, and its lowest value of $350.0 million during Q4 2023.
  • For the 3-year period, Royalty Pharma's Long-Term Debt Issuances averaged around $1.2 billion, with its median value being $1.3 billion (2021).
  • Data for Royalty Pharma's Long-Term Debt Issuances shows a peak YoY increase of 7825.11% (in 2021) and a maximum YoY decrease of 7825.11% (in 2021) over the last 5 years.
  • Quarter analysis of 3 years shows Royalty Pharma's Long-Term Debt Issuances stood at $1.3 billion in 2021, then plummeted by 72.5% to $350.0 million in 2023, then soared by 458.42% to $2.0 billion in 2025.
  • Its last three reported values are $2.0 billion in Q3 2025, $350.0 million for Q4 2023, and $1.3 billion during Q3 2021.